Dr. Chandarlapaty on Role of the PI3K Pathway in Breast Cancer

Sarat Chandarlapaty, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of the PI3K pathway in patients with metastatic breast cancer.

Although there has not been an agent yet developed that successfully targets PI3K, Chandalapty says the pathway still has a significant role.

PI3K mutations may be less frequent than AKT mutations in patients with metastatic breast cancer, he adds. However, developing a drug that specifically targets PI3K-mutant tumors may help researchers in achieving activity in a difficult-to-treat population.